Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation Development and Characterization of Controlled Release Core-in-cup Matrix Tablets of Venlafaxine HCl

Author(s): Balaji Maddiboyina, Vikas Jhawat*, Gandhi Sivaraman, Omprakash Sunnapu, Ramya Krishna Nakkala, Mudavath Hanuma Naik and Monika Gulia

Volume 15, Issue 5, 2020

Page: [503 - 511] Pages: 9

DOI: 10.2174/1574885515666200331104440

Price: $65

Abstract

Background: Venlafaxine HCl is a selective serotonin reuptake inhibitor, which is given in the treatment of depression. The delivery of the drug at a controlled rate can be of great importance for a prolonged effect.

Objective: The objective was to prepare and optimize the controlled release core in a cup matrix tablet of venlafaxine HCl using the combination of hydrophilic and hydrophobic polymers to prolong the effect with rate controlled drug release.

Methods: The controlled release core in cup matrix tablets of venlafaxine HCl was prepared using HPMC K5, K4, K15, HCO, IPA, aerosol, magnesium stearate, hydrogenated castor oil and micro crystalline cellulose PVOK-900 using wet granulation technique. Total ten formulations with varying concentrations of polymers were prepared and evaluated for different physicochemical parameters such FTIR analysis for drug identification. In-vitro drug dissolution study was performed to evaluate the amount of drug release in 24 hrs, drug release kinetics study was performed to fit the data in zero order, first order, Hixson-crowell and Higuchi equation to determine the mechanism of drug release and stability studies for 3 months as observed.

Results: The results of hardness, thickness, weight variation, friability and drug content study were in an acceptable range for all formulations. Based on the in vitro dissolution profile, formulation F-9was considered to be the optimized, extending the release of 98.32% of drug up to 24 hrs. The data fitting study showed that the optimized formulation followed the zero order release rate kinetics and when compared with the innovator product (flavix XR), showed better drug release profile.

Conclusion: The core-in-cup technology has the potential to control the release rate of freely water soluble drugs for single administration per day by optimization with the combined use of hydrophilic and hydrophobic polymers.

Keywords: Venlafaxine HCl, polymers, controlled release, core and cup, HPMC, wet granulation, matrix tablets.

« Previous Next »
Graphical Abstract

[1]
Shidhaye S, Dhone A, Budhkar T. Technologies in pulsatile drug delivery system. Int J Adv Pharm Biol Chem 2012; 1: 438-45.
[2]
Balaji M, Abhay A, Gyati SA, et al. Formulation and Characterization of Polycarbophil Coated Mucoadhesive Microspheres of Repaglinide. J Pharm Sci & Res 2015; 7(11): 972-7.
[3]
Danckwerts MP, Vander WJG. The effect of processing variables on the compression properties of controlled release core-in-cup compressed tablets from a new adjustable punch. Int J Pharm 1995; 123: 85-94.
[http://dx.doi.org/10.1016/0378-5173(95)00043-I]
[4]
Banker GS, Anderson NR. The theory and practice of Industrial Pharmacy. Mumbai: Varghese Publishing House 1987; pp. 293-45.
[5]
Dierick M. A review of the efficacy and tolerability of venlafaxine. Eur Psychiatry 1997; 12(Suppl. 4): 307s-13s.
[http://dx.doi.org/10.1016/S0924-9338(97)83310-X] [PMID: 19698585]
[6]
Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological and behavioural effects of Wy-45,233, its enantiomers and otheridentified metabolites of the anti-depressant venlafaxine. Drug Dev Res 1991; 23: 191-9.
[http://dx.doi.org/10.1002/ddr.430230210]
[7]
Effexor XR. Philadelphia, PA 19101: Wyeth Pharma Inc 2003. Sep; Venlafaxine Extended Release Capsules] Product Information
[8]
Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996; 16(3): 54S-9S.
[http://dx.doi.org/10.1097/00004714-199606002-00011] [PMID: 8784648]
[9]
Troy SM, Dilea C, Martin PT, Leister CA, Fruncillo RJ, Chiang ST. Pharmacokinetics of once-daily venlafaxine Extended release in healthy volunteers. Curr Ther Res Clin Exp 1997; 58: 504-14.
[http://dx.doi.org/10.1016/S0011-393X(97)80042-2]
[10]
Reddy KR, Mutalik S, Reddy S. Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS PharmSciTech 2003; 4(4)E61
[http://dx.doi.org/10.1208/pt040461] [PMID: 15198556]
[11]
Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci 1967; 56(10): 1238-42.
[http://dx.doi.org/10.1002/jps.2600561005] [PMID: 6059440]
[12]
Higuchi T. Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52: 1145-9.
[http://dx.doi.org/10.1002/jps.2600521210] [PMID: 14088963]
[13]
Korsmeyer R, Gurny R, Doelker E, Buri P, Peppas N. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25-35.
[http://dx.doi.org/10.1016/0378-5173(83)90064-9]]
[14]
Gohel MC, Amin AF, Patel KV, Panchal MK. Studies in release behavior of diltiazem HCl from matrix tablets containing (hydroxypropyl)methyl cellulose and xanthan gum. Boll Chim Farm 2002; 141(1): 21-8.
[PMID: 12064053]
[15]
United States Pharmacopoeia XXIX. The United States Pharmacopoeial Convention Inc 2006.
[16]
Srinija K, Lakshmi PK. Novel core in cup (In-lay) tablets of lamotrigine for mucoadhesive drug delivery system. Int Curr Pharm J 2016; 5: 9-13.
[http://dx.doi.org/10.3329/icpj.v5i2.26440]]
[17]
Li CJ, Zhu JB, Yu WY. Preparation of verapamil hydrochloride core-in-cup tablets with double-pulsatile and multi-phasic release. Yao Xue Xue Bao 2008; 43(6): 652-6.
[PMID: 18822971]
[18]
Nagaraju R, Meera DS, Kaza R, Arvind VV, Venkateswarlu V. Core-in-cup tablet design of metoprolol succinate and its evaluation for controlled release. Curr Drug Discov Technol 2009; 6(4): 299-305.
[http://dx.doi.org/10.2174/157016309789869029] [PMID: 20025598]

Rights & Permissions Print Cite
Article Metrics
34
© 2024 Bentham Science Publishers | Privacy Policy